- Campbell's Soup CEO: 'I Have Never Seen Industry Conditions Like Today'
- Want to Know the Real Problem With the U.S. Economy?
- Tesla Tanks as GE Eyes Energy Storage Role, Baidu Plunges on Weak Forecast
- I Got a Perfect Credit Score: Here's How You Can Do It, Too
- Government Says Fiat Chrysler Must Offer to Buy Back 500,000 Pickups
Investor confidence in biotech stocks is shaky following last week's Biogen blow-up, making Tuesday's Gilead earnings even more important.
U.S.-listed Chinese stocks were under pressure after China's stock market fell at the fastest pace since 2007 on Monday.
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
The CNBC "Fast Money" traders look at recent earnings and consider whether dips in stock and oil prices present opportunities for investors.
More earnings and new phones from Motorola are also on the list of what to watch.
Amazon (AMZN) blew past earnings estimates, posting a surprise profit, thanks to strong growth in Prime memberships.
Biogen failed to deliver on its latest earnings report, which is why the stock is being sold off more than 16% on Friday, Cramer said.
Anthem (WLP) has made it official. It's buying Cigna (CI) for $54.2 billion, creating a health insurance giant.
Biogen, AbbVie and Spirit Airlines are also reporting results on Friday, and the PMI flash manufacturing index is notable on the economic calendar.
For Friday July 24, TheStreet awaits quarterly financial results from Biogen (BIIB), AbbVie (ABBV), American Airlines Group (AAL), and Spirit Airlines (SAVE).
Although shares of Exact Sciences have fallen 18% over the past month, its cancer screening product Cologuard is already in use at the Mayo Clinic.
A lot of stocks we follow are continuing their upward moves after a brief market swoon.
The threat of higher rates ahead has kept REIT shares in check in 2015, but these REITs have strong outlooks and are poised to do well, one fund manager says.
Exact Sciences (EXAS) shares have pulled back in the past month due to a secondary offering and profit taking after a huge run-up.
The threat of higher rates ahead has kept REIT shares in check so far in 2015.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV